Tumor antigen TRAG-3 mimotope peptide and application thereof

A technology of TRAG-3 and mimic epitope, which is applied in the field of tumor antigen mimic epitope peptide, can solve the problems of increasing CTL immune response strength and anti-peptidase degradation ability, easy to be degraded by peptidase, and difficult uptake of natural epitope peptide , to achieve the effects of good development and application prospects, strong affinity, and strong CTL-specific killing effect
CN101619092AInactive Publication Date: 2010-01-06THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
0 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
Publication Date
2010-01-06
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a tumor antigen TRAG-3 mimic epitope peptide and an application thereof. The mimic epitope peptide comprises an amino acid sequence shown by Ile-Leu-Leu-Arg-Asp-Ala-Gly-Leu-Val, wherein the fifth Asp is D-Asp or the sixth Ala is D-Ala. The mimic epitope peptide has the advantages of better enzymic degradation resistant stability compared with TRAG-3 natural epitope peptide, stronger appetency compared with HLA-A2.1, and stronger CTL specific killing effect compared with TRAG-3 positive tumor cells, can be used for preparing polypeptide vaccine for treating the TRAG-3 positive tumor cells, and has good development and application prospect in the immunotherapy filed.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a tumor antigen mimic epitope peptide, in particular to a tumor antigen TRAG-3 mimic epitope peptide, and also relates to the application of the mimic epitope peptide. Background technique

[0002] Malignant tumors are diseases with high morbidity and high mortality that seriously threaten human health. Its treatment methods mainly include surgical resection, radiotherapy and chemical drug treatment, but the therapeutic effects of these methods on some tumors, especially advanced malignant tumors are not satisfactory. In recent years, tumor immunotherapy has developed rapidly as the fourth treatment method for malignant tumors. A large number of literatures have reported that tumor vaccines based on tumor antigen cytotoxic T lymphocyte (CTL) epitopes can effectively induce the production of specific tumor-killing CTLs in vivo, so that the disease of some patients can be controlled and alleviated, while it has no effect on norm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More